Aclarion

Moat components and durability assessment: Intangible assets and data (score 35/100; weight 40%): Aclarion reports 64 issued and pending patents globally and a growing clinical evidence base, including peer‑reviewed work linking MRS biomarkers to improved surgical outcomes.

However, MR spectroscopy is not proprietary to one vendor, and algorithms may face replication risk over time without rapid data‑network compounding. Weighting this as the main potential moat yields a modest score until large-scale, payer‑validated outcomes accumulate.

Network effects (score 15/100; weight 15%): A data advantage could emerge if high‑volume adoption compounds training data across scanner makes/sites, but current installed base and revenue are too small to evidence true network effects.

Switching costs (score 20/100; weight 20%): Integration into spine care workflows can create moderate stickiness once surgeons rely on Nociscan outputs, yet alternatives (standard MRI interpretation, SPECT‑CT, or invasive discography) remain available and entrenched.

Cost advantage (score 15/100; weight 10%): SaaS delivery suggests high gross margin potential at scale, but today’s volumes are insufficient to demonstrate structural cost leadership.

Efficient scale (score 20/100; weight 15%): The market (nearly 6 million U.S. lumbar MRIs annually) is large; Nociscan does not benefit from geographic natural monopolies.

Overall, moat durability depends on converting outcomes evidence into reimbursement and entrenched practice patterns; current proof is insufficient for a durable, multi‑moat score. Key sources: 10‑K 2025 on IP and classification; Q1 2026 PR on patents; PubMed outcomes paper; CLARITY protocol.